{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T21:52:42Z","timestamp":1792878762357,"version":"4.5.0"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,26]],"date-time":"2023-10-26T00:00:00Z","timestamp":1698278400000},"content-version":"am","delay-in-days":329,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100015615","name":"National Drug Abuse Treatment Clinical Trials Network","doi-asserted-by":"publisher","award":["HHSN271201500065C"],"award-info":[{"award-number":["HHSN271201500065C"]}],"id":[{"id":"10.13039\/100015615","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015615","name":"National Drug Abuse Treatment Clinical Trials Network","doi-asserted-by":"publisher","award":["K01DA053435"],"award-info":[{"award-number":["K01DA053435"]}],"id":[{"id":"10.13039\/100015615","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015615","name":"National Drug Abuse Treatment Clinical Trials Network","doi-asserted-by":"publisher","award":["K23DA042140"],"award-info":[{"award-number":["K23DA042140"]}],"id":[{"id":"10.13039\/100015615","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015615","name":"National Drug Abuse Treatment Clinical Trials Network","doi-asserted-by":"publisher","award":["R25DA037190"],"award-info":[{"award-number":["R25DA037190"]}],"id":[{"id":"10.13039\/100015615","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015615","name":"National Drug Abuse Treatment Clinical Trials Network","doi-asserted-by":"publisher","award":["T32HS026120"],"award-info":[{"award-number":["T32HS026120"]}],"id":[{"id":"10.13039\/100015615","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015615","name":"National Drug Abuse Treatment Clinical Trials Network","doi-asserted-by":"publisher","award":["U10DA013045"],"award-info":[{"award-number":["U10DA013045"]}],"id":[{"id":"10.13039\/100015615","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015615","name":"National Drug Abuse Treatment Clinical Trials Network","doi-asserted-by":"publisher","award":["U10DA013046"],"award-info":[{"award-number":["U10DA013046"]}],"id":[{"id":"10.13039\/100015615","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015615","name":"National Drug Abuse Treatment Clinical Trials Network","doi-asserted-by":"publisher","award":["U10DA015833"],"award-info":[{"award-number":["U10DA015833"]}],"id":[{"id":"10.13039\/100015615","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015615","name":"National Drug Abuse Treatment Clinical Trials Network","doi-asserted-by":"publisher","award":["UG1\/U10DA013034"],"award-info":[{"award-number":["UG1\/U10DA013034"]}],"id":[{"id":"10.13039\/100015615","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015615","name":"National Drug Abuse Treatment Clinical Trials Network","doi-asserted-by":"publisher","award":["UG1\/U10DA013035"],"award-info":[{"award-number":["UG1\/U10DA013035"]}],"id":[{"id":"10.13039\/100015615","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015615","name":"National Drug Abuse Treatment Clinical Trials Network","doi-asserted-by":"publisher","award":["UG1\/U10DA013714"],"award-info":[{"award-number":["UG1\/U10DA013714"]}],"id":[{"id":"10.13039\/100015615","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015615","name":"National Drug Abuse Treatment Clinical Trials Network","doi-asserted-by":"publisher","award":["UG1\/U10DA013720"],"award-info":[{"award-number":["UG1\/U10DA013720"]}],"id":[{"id":"10.13039\/100015615","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015615","name":"National Drug Abuse Treatment Clinical Trials Network","doi-asserted-by":"publisher","award":["UG1\/U10DA013732"],"award-info":[{"award-number":["UG1\/U10DA013732"]}],"id":[{"id":"10.13039\/100015615","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015615","name":"National Drug Abuse Treatment Clinical Trials Network","doi-asserted-by":"publisher","award":["UG1\/U10DA015831"],"award-info":[{"award-number":["UG1\/U10DA015831"]}],"id":[{"id":"10.13039\/100015615","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000133","name":"AHRQ","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000133","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journalofsubstanceabusetreatment.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Substance Abuse Treatment"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.jsat.2022.108830","type":"journal-article","created":{"date-parts":[[2022,6,22]],"date-time":"2022-06-22T11:33:34Z","timestamp":1655897614000},"page":"108830","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["Polysubstance use before and during treatment with medication for opioid use disorder: Prevalence and association with treatment outcomes"],"prefix":"10.1016","volume":"143","author":[{"given":"Amanda M.","family":"Bunting","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noa","family":"Krawczyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tse-Hwei","family":"Choo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Pavlicova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"McNeely","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Babak","family":"Tofighi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Rotrosen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Nunes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua D.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"25","key":"10.1016\/j.jsat.2022.108830_bb0005","first-page":"1","article-title":"The ASAM national practice guideline for the treatment of opioid use disorder: 2020 focused update","volume":"14","year":"2019","journal-title":"Journal of Addiction Medicine"},{"key":"10.1016\/j.jsat.2022.108830_bb0010","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.jsat.2014.12.011","article-title":"Discontinuation of buprenorphine maintenance therapy: Perspectives and outcomes","volume":"52","author":"Bentzley","year":"2015","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"7","key":"10.1016\/j.jsat.2022.108830_bb0015","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1111\/add.13339","article-title":"Differences in polysubstance use patterns and drug-related outcomes between people who inject drugs receiving and not receiving opioid substitution therapies","volume":"111","author":"Betts","year":"2016","journal-title":"Addiction"},{"key":"10.1016\/j.jsat.2022.108830_bb0020","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.1097\/MLR.0000000000000731","article-title":"Clinical epidemiology of single versus multiple substance use disorders: Polysubstance use disorder","volume":"55","author":"Bhalla","year":"2017","journal-title":"Medical Care"},{"issue":"1","key":"10.1016\/j.jsat.2022.108830_bb0025","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1093\/epirev\/mxaa005","article-title":"The association of co-occurring substance use and the effectiveness of opiate treatment programs by intervention type: A systematic review","volume":"42","author":"Blondino","year":"2020","journal-title":"Epidemiologic Reviews"},{"issue":"1","key":"10.1016\/j.jsat.2022.108830_bb0030","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1111\/nyas.12501","article-title":"Lost in translation? Moving contingency management and cognitive behavioral therapy into clinical practice","volume":"1327","author":"Carroll","year":"2014","journal-title":"Annals of the New York Academy of Sciences"},{"key":"10.1016\/j.jsat.2022.108830_bb0035","series-title":"Clinical guidelines for the use of buprenorphine in the treatment of opioid addiction. treatment improvement protocol (TIP) series 40. DHHS publication no. (SMA) 04\u20103939","author":"Center for Substance Abuse Treatment","year":"2004"},{"key":"10.1016\/j.jsat.2022.108830_bb0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2020.108193","article-title":"A systematic review and meta-analysis of medications for stimulant use disorders in patients with co-occurring opioid use disorders","volume":"216","author":"Chan","year":"2020","journal-title":"Drug and Alcohol Dependence"},{"issue":"3","key":"10.1016\/j.jsat.2022.108830_bb0045","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1081\/ADA-100104511","article-title":"Concurrent substance use and outcome in combined behavioral and naltrexone therapy for opiate dependence","volume":"27","author":"Church","year":"2001","journal-title":"The American Journal of Drug and Alcohol Abuse"},{"issue":"2S Suppl 1","key":"10.1016\/j.jsat.2022.108830_bb0050","first-page":"1","article-title":"The ASAM national practice guideline for the treatment of opioid use disorder: 2020 focused update","volume":"14","author":"Cunningham","year":"2020","journal-title":"Journal of Addiction Medicine"},{"issue":"4","key":"10.1016\/j.jsat.2022.108830_bb0055","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1111\/j.1521-0391.2013.12032.x","article-title":"Buprenorphine treatment outcomes among opioid-dependent cocaine users and non-users","volume":"22","author":"Cunningham","year":"2013","journal-title":"The American Journal on Addictions"},{"issue":"2","key":"10.1016\/j.jsat.2022.108830_bb0060","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1080\/10550490050173217","article-title":"The effect of stimulant and sedative use on treatment outcome of patients admitted to methadone maintenance treatment","volume":"9","author":"Demaria","year":"2000","journal-title":"American Journal on Addictions"},{"key":"10.1016\/j.jsat.2022.108830_bb0065","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.drugalcdep.2018.08.029","article-title":"Twin epidemics: The surging rise of methamphetamine use in chronic opioid users","volume":"193","author":"Ellis","year":"2018","journal-title":"Drug and Alcohol Dependence"},{"issue":"11","key":"10.1016\/j.jsat.2022.108830_bb0070","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0027244","article-title":"Typologies of prescription opioid use in a large sample of adults assessed for substance abuse treatment","volume":"6","author":"Green","year":"2011","journal-title":"PLoS ONE"},{"issue":"1","key":"10.1016\/j.jsat.2022.108830_bb0075","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/add.12333","article-title":"Treatment retention among patients randomized to buprenorphine\/naloxone compared to methadone in a multi-site trial","volume":"109","author":"Hser","year":"2014","journal-title":"Addiction (Abingdon, England)"},{"issue":"2","key":"10.1016\/j.jsat.2022.108830_bb0080","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1111\/add.14812","article-title":"Increases in methamphetamine use among heroin treatment admissions in the United States, 2008\u201317","volume":"115","author":"Jones","year":"2020","journal-title":"Addiction (Abingdon, England)"},{"key":"10.1016\/j.jsat.2022.108830_bb0085","doi-asserted-by":"crossref","DOI":"10.15585\/mmwr.mm6817a3","article-title":"Drug overdose deaths involving cocaine and psychostimulants with abuse potential\u2014United States, 2003\u20132017","volume":"68","author":"Kariisa","year":"2019","journal-title":"MMWR. Morbidity and Mortality Weekly Report"},{"key":"10.1016\/j.jsat.2022.108830_bb0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsat.2021.108329","article-title":"Who stays in medication treatment for opioid use disorder? A national study of outpatient specialty treatment settings","volume":"126","author":"Krawczyk","year":"2021","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1016\/j.jsat.2022.108830_bb0095","doi-asserted-by":"crossref","first-page":"101939","DOI":"10.1016\/j.cpr.2020.101939","article-title":"The relationship between cannabis use and patient outcomes in medication-based treatment of opioid use disorder: A systematic review","volume":"82","author":"Lake","year":"2020","journal-title":"Clinical Psychology Review"},{"issue":"10118","key":"10.1016\/j.jsat.2022.108830_bb0100","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0140-6736(17)32812-X","article-title":"Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): A multicentre, open-label, randomised controlled trial","volume":"391","author":"Lee","year":"2018","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.jsat.2022.108830_bb0105","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.cct.2016.08.004","article-title":"NIDA clinical trials network CTN-0051, extended-release naltrexone vs. Buprenorphine for opioid treatment (X:BOT): Study design and rationale","volume":"50","author":"Lee","year":"2016","journal-title":"Contemporary Clinical Trials"},{"issue":"1","key":"10.1016\/j.jsat.2022.108830_bb0110","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1111\/add.15116","article-title":"Polysubstance use and association with opioid use disorder treatment in the US veterans health administration","volume":"116","author":"Lin","year":"2020","journal-title":"Addiction"},{"key":"10.1016\/j.jsat.2022.108830_bb0115","series-title":"Conceptualizing stigma","first-page":"363","volume":"27","author":"Link","year":"2001"},{"key":"10.1016\/j.jsat.2022.108830_bb0120","doi-asserted-by":"crossref","DOI":"10.15585\/mmwr.mm7034a2","article-title":"Trends in nonfatal and fatal overdoses involving benzodiazepines\u201438 states and the District of Columbia, 2019\u20132020","volume":"70","author":"Liu","year":"2021","journal-title":"MMWR. Morbidity and Mortality Weekly Report"},{"issue":"1","key":"10.1016\/j.jsat.2022.108830_bb0125","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1046\/j.1360-0443.1998.931516.x","article-title":"Pre- and in-treatment predictors of retention in methadone treatment using survival analysis","volume":"93","author":"Magura","year":"1998","journal-title":"Addiction"},{"issue":"4","key":"10.1016\/j.jsat.2022.108830_bb0130","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1037\/1064-1297.13.4.293","article-title":"Predictors of outcome in LAAM, buprenorphine, and methadone treatment for opioid dependence","volume":"13","author":"Marsch","year":"2005","journal-title":"Experimental and Clinical Psychopharmacology"},{"issue":"9","key":"10.1016\/j.jsat.2022.108830_bb0135","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.addbeh.2009.04.012","article-title":"Mono- and polysubstance dependent subjects differ on social factors, childhood trauma, personality, suicidal behaviour, and comorbid Axis I diagnoses","volume":"34","author":"Martinotti","year":"2009","journal-title":"Addictive Behaviors"},{"key":"10.1016\/j.jsat.2022.108830_bb0140","doi-asserted-by":"crossref","DOI":"10.15585\/mmwr.mm6935a1","article-title":"Vital signs: Characteristics of drug overdose deaths involving opioids and stimulants \u2014 24 states and the District of Columbia, January\u2013June 2019","volume":"69","author":"O\u2019Donnell","year":"2020","journal-title":"MMWR. Morbidity and Mortality Weekly Report"},{"key":"10.1016\/j.jsat.2022.108830_bb0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2020.108089","article-title":"Trends in characteristics of individuals who use methamphetamine in the United States, 2015\u20132018","volume":"213","author":"Palamar","year":"2020","journal-title":"Drug and Alcohol Dependence"},{"issue":"5","key":"10.1016\/j.jsat.2022.108830_bb0150","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1111\/add.14886","article-title":"Associations between prescribed benzodiazepines, overdose death and buprenorphine discontinuation among people receiving buprenorphine","volume":"115","author":"Park","year":"2020","journal-title":"Addiction"},{"issue":"6","key":"10.1016\/j.jsat.2022.108830_bb0155","doi-asserted-by":"crossref","first-page":"601","DOI":"10.3109\/14659891.2015.1118564","article-title":"Outcome predictors for patients receiving methadone maintenance treatment: Findings from a retrospective multi-site study","volume":"21","author":"Proctor","year":"2016","journal-title":"Journal of Substance Use"},{"issue":"1","key":"10.1016\/j.jsat.2022.108830_bb0160","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1037\/a0030992","article-title":"Reliability of the timeline followback for cocaine, cannabis, and cigarette use","volume":"28","author":"Robinson","year":"2014","journal-title":"Psychology of Addictive Behaviors"},{"issue":"3","key":"10.1016\/j.jsat.2022.108830_bb0165","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.drugalcdep.2013.04.006","article-title":"Benzodiazepine use during buprenorphine treatment for opioid dependence: Clinical and safety outcomes","volume":"132","author":"Schuman-Olivier","year":"2013","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1016\/j.jsat.2022.108830_bb0170","series-title":"Measuring alcohol consumption: Psychosocial and biological methods","first-page":"41","article-title":"Timeline follow-back: A technique for assessing self-reported alcohol consumption","author":"Sobell","year":"1992"},{"key":"10.1016\/j.jsat.2022.108830_bb0175","series-title":"Medications for Opioid Use Disorder (No. PEP20-02-01\u2013006; Treatment Improvement Protocol (TIP) Series 63)","year":"2021"},{"key":"10.1016\/j.jsat.2022.108830_bb0180","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.jsat.2019.10.005","article-title":"Association between methamphetamine use and retention among patients with opioid use disorders treated with buprenorphine","volume":"109","author":"Tsui","year":"2020","journal-title":"Journal of Substance Abuse Treatment"}],"container-title":["Journal of Substance Abuse Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S074054722200112X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S074054722200112X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T19:58:35Z","timestamp":1760039915000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S074054722200112X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":36,"alternative-id":["S074054722200112X"],"URL":"https:\/\/doi.org\/10.1016\/j.jsat.2022.108830","relation":{},"ISSN":["0740-5472"],"issn-type":[{"value":"0740-5472","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Polysubstance use before and during treatment with medication for opioid use disorder: Prevalence and association with treatment outcomes","name":"articletitle","label":"Article Title"},{"value":"Journal of Substance Abuse Treatment","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jsat.2022.108830","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"108830"}}